LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 325 of 535
Next
>>
>
8101 to 8125 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dovitinib	0.04	uM	LJP5	1	E24	72	hr	1097	3454	3735	0.9247	0.9134
BT-20	Dovitinib	0.04	uM	LJP5	2	E24	72	hr	1097	3307	3877	0.8528	0.8326
BT-20	Dovitinib	0.04	uM	LJP5	3	E24	72	hr	1097	3581	3925	0.9123	0.9026
BT-20	Dovitinib	0.12	uM	LJP5	1	E23	72	hr	1097	2387	3735	0.6391	0.5524
BT-20	Dovitinib	0.12	uM	LJP5	2	E23	72	hr	1097	2689	3877	0.6934	0.6358
BT-20	Dovitinib	0.12	uM	LJP5	3	E23	72	hr	1097	2562	3925	0.6527	0.5859
BT-20	Dovitinib	0.37	uM	LJP5	1	E22	72	hr	1097	1664	3735	0.4455	0.2657
BT-20	Dovitinib	0.37	uM	LJP5	2	E22	72	hr	1097	1640	3877	0.4229	0.2469
BT-20	Dovitinib	0.37	uM	LJP5	3	E22	72	hr	1097	1570	3925	0.4000	0.2151
BT-20	Dovitinib	1.11	uM	LJP5	1	E21	72	hr	1097	1502	3735	0.4021	0.1944
BT-20	Dovitinib	1.11	uM	LJP5	2	E21	72	hr	1097	1521	3877	0.3922	0.1964
BT-20	Dovitinib	1.11	uM	LJP5	3	E21	72	hr	1097	1724	3925	0.4392	0.2785
BT-20	Dovitinib	3.33	uM	LJP5	1	E20	72	hr	1097	1469	3735	0.3933	0.1795
BT-20	Dovitinib	3.33	uM	LJP5	2	E20	72	hr	1097	1457	3877	0.3757	0.1685
BT-20	Dovitinib	3.33	uM	LJP5	3	E20	72	hr	1097	1576	3925	0.4015	0.2176
BT-20	Dovitinib	10	uM	LJP5	1	E19	72	hr	1097	1396	3735	0.3737	0.1460
BT-20	Dovitinib	10	uM	LJP5	2	E19	72	hr	1097	1324	3877	0.3414	0.1086
BT-20	Dovitinib	10	uM	LJP5	3	E19	72	hr	1097	1352	3925	0.3444	0.1202
BT-20	GSK 690693	0.04	uM	LJP5	1	F24	72	hr	1097	3428	3735	0.9178	0.9052
BT-20	GSK 690693	0.04	uM	LJP5	2	F24	72	hr	1097	3097	3877	0.7987	0.7677
BT-20	GSK 690693	0.04	uM	LJP5	3	F24	72	hr	1097	3193	3925	0.8134	0.7876
BT-20	GSK 690693	0.12	uM	LJP5	1	F23	72	hr	1097	2816	3735	0.7539	0.7046
BT-20	GSK 690693	0.12	uM	LJP5	2	F23	72	hr	1097	3002	3877	0.7742	0.7378
BT-20	GSK 690693	0.12	uM	LJP5	3	F23	72	hr	1097	2899	3925	0.7385	0.6961
BT-20	GSK 690693	0.37	uM	LJP5	1	F22	72	hr	1097	2077	3735	0.5561	0.4349

|<
<<
Previous
Page 325 of 535
Next
>>
>
8101 to 8125 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)